Global Cancer/Tumor Profiling Market Size study & Forecast, by Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, and Other Cancer), Biomarker Type (Genomic Biomarker and Protein Biomarker), Technology, Technique

The Global Cancer/Tumor Profiling Market is valued at approximately USD 10.73 billion in 2024 and is anticipated to grow at a CAGR of more than 12.50% over the forecast period 2025-2035. Cancer/Tumor Profiling refers to the process of analyzing genetic mutations, biomarker expressions, and molecular signatures to better understand the nature of cancer and its progression. By providing a personalized view of each tumor, profiling helps physicians identify the most effective treatment pathways, predict drug response, and monitor patient outcomes with higher precision. This rapidly advancing field is propelled by the rising prevalence of cancer worldwide, growing adoption of precision medicine, and increasing investments in next-generation sequencing technologies. Moreover, the integration of advanced bioinformatics platforms is further accelerating the pace at which clinicians and researchers can decode the molecular complexity of cancer.

The surge in global cancer incidence has intensified the demand for profiling solutions as stakeholders look to shift away from a one-size-fits-all approach to oncology care. According to the World Health Organization, cancer accounted for nearly 10 million deaths in 2022, with breast, lung, and colorectal cancers ranking among the most common. These alarming figures underscore the urgency for better diagnostic, prognostic, and therapeutic tools. Tumor profiling has consequently emerged as a cornerstone in personalized medicine, enabling early detection and guiding targeted treatment. The rapid progress of molecular diagnostic technologies, particularly next-generation sequencing and mass spectrometry, has lowered costs and improved efficiency, thus making profiling more accessible across hospitals, research institutes, and diagnostic centers. However, high testing costs, coupled with limited infrastructure in underdeveloped regions, still pose challenges to widespread adoption.

The detailed segments and sub-segments included in the report are:

By Cancer Type:
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma Cancer
• Other Cancer

By Biomarker Type:
• Genomic Biomarker
• Protein Biomarker

By Technology:
• Immunoassays
• Next-Generation Sequencing
• Polymerase Chain Reaction
• Mass Spectrometry
• In-Situ Hybridization
• Microarrays
• Others

By Technique:
• Genomics
• Proteomics
• Metabolomics
• Epigenetics

By Application:
• Research
• Biomarker Discovery
• Personalized Medicine
• Clinical Application
• Diagnostics
• Prognostics
• Screening
• Treatment
• Monitoring

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Breast Cancer is Expected to Dominate the Market

Breast cancer profiling is projected to dominate the cancer/tumor profiling market during the forecast period. This dominance stems from the rising global prevalence of breast cancer, extensive screening initiatives, and the rapid integration of genomic and proteomic profiling techniques in breast cancer diagnostics. Advancements in biomarker-based assays and targeted therapies have elevated the demand for comprehensive profiling to identify tumor-specific drivers. Furthermore, increasing awareness campaigns, government-supported early detection programs, and an upsurge in funding for breast cancer research have reinforced its position as the largest revenue-generating segment in this domain.

Next-Generation Sequencing Leads in Revenue Contribution

By technology, Next-Generation Sequencing (NGS) continues to be the leading contributor to the market’s revenue. Its capability to simultaneously analyze millions of DNA fragments offers unparalleled speed and accuracy in decoding tumor heterogeneity. While immunoassays and PCR techniques remain critical for routine applications due to their affordability and accessibility, NGS has become indispensable in advanced oncology research and clinical trials. Additionally, the technology’s declining costs, coupled with increasing adoption in both developed and developing healthcare systems, are propelling its growth further. The picture is twofold: NGS dominates the market in revenue terms, whereas complementary technologies like immunoassays are expected to maintain strong adoption in cost-sensitive settings.

The key regions considered for the Global Cancer/Tumor Profiling Market study include Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. North America held the largest share in 2025, supported by advanced healthcare infrastructure, a high prevalence of cancer, and strong R&D investments by biotechnology firms. The presence of leading market players, favorable reimbursement policies, and rapid adoption of advanced diagnostic platforms further boost the region’s dominance. Meanwhile, Asia Pacific is projected to be the fastest-growing region, driven by the rise in cancer incidence, growing awareness of precision medicine, and expanding healthcare infrastructure in countries like China and India. Government support for genomic research and increasing collaborations between regional hospitals and global biotech firms are expected to accelerate demand for tumor profiling across APAC.

Major market players included in this report are:
• Illumina, Inc.
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.
• QIAGEN N.V.
• Agilent Technologies, Inc.
• PerkinElmer, Inc.
• Guardant Health, Inc.
• Exact Sciences Corporation
• Caris Life Sciences
• Nanostring Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• HTG Molecular Diagnostics, Inc.
• Foundation Medicine, Inc.
• Genomic Health, Inc.
• Eurofins Scientific

Global Cancer/Tumor Profiling Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period - 2025-2035
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of the competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more